Add-On Aliskiren Elicits Stronger Renoprotection Than High-Dose Valsartan in Type 2 Diabetic KKAy Mice That Do Not Respond to Low-Dose Valsartan

Add-On Aliskiren Elicits Stronger Renoprotection Than High-Dose Valsartan in Type 2 Diabetic KKAy Mice That Do Not Respond to Low-Dose Valsartan

We hypothesized that aliskiren provides renoprotection in diabetic animals that did not receive sufficient renoprotection by AT1-receptor antagonist treatment. Type 2 diabetic KKAy mice were treated with group 1: vehicle or group 2: valsartan (15 mg/kg per day) from 12 to 16 weeks of age. The mice w...

Full description

Bibliographic Details
Main Authors:	Bai Lei, Daisuke Nakano, Yu-Yan Fan, Kento Kitada, Hirofumi Hitomi, Hiroyuki Kobori, Hirohito Mori, Tsutomu Masaki, Akira Nishiyama
Format:	Article
Language:	English
Published:	Elsevier 2012-01-01
Series:	Journal of Pharmacological Sciences
Online Access:	http://www.sciencedirect.com/science/article/pii/S1347861319305055

Similar Items

Aliskiren and valsartan combination therapy for the management of hypertension
by: Benjamin J Epstein
Published: (2010-08-01)

Protective effects of aliskiren and valsartan in mice with diabetic nephropathy
by: Weidong Wang, et al.
Published: (2014-12-01)

Aliskiren and valsartan in combination is a promising therapy for hypertensive renal injury in rats
by: Hala Salah Abdel Kawy
Published: (2018-08-01)

The association of gene polymorphism with diabetic kidney disease and renoprotective efficacy of valsartan
by: Yuying Wang, et al.
Published: (2016-09-01)

Efficacy of aliskiren and valsartan in hypertensive patients with albuminuria: a randomized parallel-group study
by: Georgios Spanos, et al.
Published: (2013-12-01)

The choice of antihypertensive therapy in correction of cognitive impairments and prevention of dementia: possibilities of valsartan and fixed-dose combination of valsartan and hydrochlorothiazide
by: O D Ostroumova, et al.
Published: (2016-12-01)

The choice of antihypertensive therapy in correction of cognitive impairments and prevention of dementia: possibilities of valsartan and fixed-dose combination of valsartan and hydrochlorothiazide
by: Ostroumova O.D., et al.
Published: (2016-12-01)

Possible renoprotective mechanisms of SGLT2 inhibitors
by: Akira Nishiyama, et al.
Published: (2023-03-01)

Role of aliskiren in blood pressure control and renoprotection
by: Hern&aacute;n Trimarchi
Published: (2011-03-01)

Amlodipine and valsartan as components of a rational and effective fixed-dose combination
by: Bernard Waeber, et al.
Published: (2009-03-01)

Effect of add-on sacubitril/valsartan on the left ventricular hypertrophy of a patient with hypertension
by: Teruhiko Imamura, et al.
Published: (2022-11-01)

First signs of reverse cardiac remodeling following one-month, low dose add-on sacubitril-valsartan therapy in patients with advanced systolic heart failure
by: Wioletta Sacharczuk, et al.
Published: (2022-03-01)

Clinical Utility of Amlodipine/Valsartan Fixed-Dose Combination in the Management of Hypertension in Chinese Patients
by: Wenbo He, et al.
Published: (2017-01-01)

Understanding the dosing-time-dependent antihypertensive effect of valsartan and aspirin through mathematical modeling
by: Javiera Cortés-Ríos, et al.
Published: (2023-03-01)

Efficacy, Safety and Tolerability of Valsartan and Hydrochlorothiazide Compared to Valsartan and Amlodipine in Stage 2 Hypertension
by: Abdul karim, et al.
Published: (2022-06-01)

Renoprotective effect of aliskiren monotherapy and aliskiren−pentoxifylline combination in hypertensive-diabetic type 2 patients with diabetic nephropathy
by: Amin T. Hamed, et al.
Published: (2013-12-01)

Two-Drug Combinations Therapy of Different Doses of Valsartan Existing Diverse Significance for Hypertensive Patients
by: Zerong Wang, et al.
Published: (2023-06-01)

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF
by: Valeria Visco, et al.
Published: (2022-10-01)

Low dose sacubitril/valsartan is effective and safe in hemodialysis patient with decompensated heart failure and hypotension
by: Yunlin Feng, MD, et al.
Published: (2022-04-01)

Sacubitril/Valsartan for heart failure
by: Wenqin Dai, MM, et al.
Published: (2022-06-01)

Formulation and characterisation of valsartan proniosomes
by: Rao Rekha
Published: (2011-04-01)

Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups
by: Assaad-Khalil SH, et al.
Published: (2015-01-01)

Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: A meta-analysis
by: Pei Yang, et al.
Published: (2022-08-01)

Different chronotherapeutic effects of valsartan and olmesartan in non-dipper hypertensive patients during valsartan treatment at morning
by: Kentaro Ushijima, et al.
Published: (2015-01-01)

Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction
by: Marc de Gasparo, et al.
Published: (2000-06-01)

Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real‐world study
by: Chen Wang, et al.
Published: (2023-06-01)

The effect of fixed-dose combination of valsartan and amlodipine on nighttime blood pressure in patients with non-dipper hypertension
by: Doğan Erdoğan, et al.
Published: (2016-07-01)

Sacubitril‐Valsartan in a routine community population: attention to volume status critical to achieving target dose
by: Rebabonye B. Pharithi, et al.
Published: (2020-02-01)

Clinical efficiency of medium and high doses of valsartan in the treatment of patient with arterial hypertension and chronic kidney diseases
by: M L Maximov, et al.
Published: (2010-12-01)

Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis
by: Hyoeun Kim, et al.
Published: (2021-08-01)

Renoprotective effects of the direct renin inhibitor aliskiren on gentamicin-induced nephrotoxicity in rats
by: Eun Hui Bae, et al.
Published: (2014-12-01)

Effect of Valsartan on the Incidence of Diabetes REPLY
by: Holman, R, et al.
Published: (2010)

Valsartan in the treatment of heart attack survivors
by: Bodh I Jugdutt
Published: (2006-06-01)

Sacubitril/valsartan: A practical guide
by: Cândida Fonseca, et al.
Published: (2019-05-01)

Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
by: Pema Raj, et al.
Published: (2021-08-01)

N‐nitrosodimethylamine‐Contaminated Valsartan and Risk of Cancer: A Nationwide Study of 1.4 Million Valsartan Users
by: Imène Mansouri, et al.
Published: (2022-12-01)

Efficacy and Safety of Valsartan or Chlorthalidone vs. Combined Valsartan and Chlorthalidone in Patients With Mild to Moderate Hypertension: The VACLOR Study
by: Fernando Manzur, et al.
Published: (2018-09-01)

Effect of High-Fat Meal on the Pharmacokinetics and Safety of Valsartan/Amlodipine Fixed Dose Combination Tablets in Healthy Subjects
by: Song H, et al.
Published: (2024-01-01)

Propafenone and valsartan overdose with cardiovascular deterioration managed with lipid emulsion and high dose insulin: a case report
by: Connie H. Yoon, et al.
Published: (2022-12-01)

COMBINATION OF DIRECT RENNIN INHIBITOR - ALISKIREN, ANGIOTENSIN II RECEPTOR BLOCKER - VALSARTAN, AND CALCIUM CHANNEL BLOCKER - AMLODIPINE, IN THERAPY OF HYPERTENSIVE PATIENT WITH GOUT (CASE REPORT)
by: O. V. Dralova, et al.
Published: (2016-01-01)